An adult has high-recurrence-risk NSCLC completely resected and has completed adjuvant platinum chemotherapy. The tumour has no targetable driver requ...

Question

An adult has high-recurrence-risk NSCLC completely resected and has completed adjuvant platinum chemotherapy. The tumour has no targetable driver requiring a different pathway. Which subsequent systemic option is NICE-supported?

Accepted Answer

Offer adjuvant pembrolizumab after surgery and platinum chemotherapy

Answer

Offer pembrolizumab before completing platinum chemotherapy

Answer

Offer pembrolizumab after incomplete macroscopic tumour resection

Answer

Offer pembrolizumab only after metastatic recurrence appears

Answer

Offer nivolumab with neoadjuvant chemotherapy after the completed surgery

COPD Pharmacologic Therapy — MRCP Part 1 MCQ

An adult has high-recurrence-risk NSCLC completely resected and has completed adjuvant platinum chemotherapy. The tumour has no targetable driver requiring a different pathway. Which subsequent systemic option is NICE-supported?